卵巢癌患者化疗所致周围神经病变的病程及其对健康相关生活质量的影响:一项纵向研究
本研究纳入荷兰南部十二家医院新诊断卵巢癌患者174例,在初始治疗后及6、12、24个月填写EORTC QLQ-OV28和EORTC QLQ-C30问卷,应答率分别为70%、71%、58%、43%。在接受化疗的98例患者中,感觉周围神经病变水平随时间保持稳定,而运动周围神经病变症状在12个月时显著改善。2年时13%仍报告高感觉周围神经病变、11%仍报告高运动周围神经病变;高感觉或高运动周围神经病变患者报告更差的生活质量,且由低转为高的患者功能恶化。
要点
- 接受化疗的卵巢癌患者中,感觉周围神经病变水平随时间保持稳定。
- 运动周围神经病变症状在12个月时显著改善。
- 2年时13%报告高感觉周围神经病变,11%报告高运动周围神经病变。
核心结论
- 在接受化疗的卵巢癌患者中,感觉周围神经病变水平随时间保持稳定,而运动周围神经病变症状在12个月时显著改善。
- 这些症状严重影响健康相关生活质量。
- 未来研究应探讨不同治疗决策和调整对化疗所致周围神经病变的影响,以便提出建议降低其患病率。
研究设计与样本
- 纵向研究,纳入荷兰南部十二家医院所有新诊断卵巢癌患者174例,在初始治疗后及6、12、24个月填写EORTC QLQ-OV28和EORTC QLQ-C30问卷,应答率分别为70%、71%、58%、43%。
- 接受化疗的患者98例纳入广义线性混合模型分析。
主要发现
- 接受化疗的患者中,感觉周围神经病变水平随时间保持稳定。
- 运动周围神经病变症状在12个月时显著改善。
- 2年时13%仍报告高感觉周围神经病变,11%仍报告高运动周围神经病变。
- 高感觉周围神经病变患者相比低感觉周围神经病变患者报告更差的躯体、角色、情绪、社会和认知功能。
- 由低感觉周围神经病变转为高的患者随时间躯体功能恶化;高运动周围神经病变患者报告更差的整体生活质量和功能;由低运动周围神经病变转为高的患者整体生活质量及躯体、角色、社会和认知功能恶化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) presents itself as sensory peripheral neuropathy (SPN) or motor peripheral neuropathy (MPN). Our aim was to examine the course of SPN and MPN, and their impact on health-related quality of life (HRQoL) among ovarian cancer patients. METHODS: All newly diagnosed ovarian cancer patients from twelve hospitals in the South of the Netherlands were eligible for participation. Patients (N=174) completed questions on CIPN (EORTC QLQ-OV28) and HRQoL (EORTC QLQ-C30) after initial treatment and at 6, 12, and 24months (response rates were 70%, 71%, 58%, and 43% respectively). RESULTS: Generalized linear mixed models showed that among chemotherapy-treated patients (N=98), SPN levels were stable over time. For MPN, symptoms significantly improved at 12months. At 2years, 13% still reported high SPN. Also, 11% still reported high MPN. Regarding HRQoL, patients with high SPN reported a worse physical, role, emotional, social, and cognitive functioning compared to those with low SPN. Moreover, those who changed from low to high SPN over time worsened on physical functioning. For MPN, a worse global quality of life and a worse functioning was reported among patients with high MPN. Also, those who changed from low to high MPN over time worsened on global quality of life and on physical, role, social, and cognitive functioning. CONCLUSIONS: Among chemotherapy-treated ovarian cancer patients, SPN levels were stable over time. In contrast, MPN symptoms significantly improved at 12months. These symptoms seriously impacted HRQoL. Future studies should examine the impact of different treatment decisions and alterations on CIPN, so recommendations can be made to reduce CIPN (prevalence).
引用
- Bonhof CS, Mols F, Vos MC, et al. Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. Gynecol Oncol. 2018. PMID: 29605500. doi:10.1016/j.ygyno.2018.03.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。